Stucco & Cement Patch by Artra-Synkoloid
Product Description
Stucco & Cement Patch was a patching and finishing compound manufactured by Artra-Synkoloid, a company that produced a range of construction and coating products during the mid-twentieth century. Sold primarily for use in building repair and surface preparation applications, this product was designed to fill cracks, holes, and surface irregularities in stucco, masonry, and concrete substrates. Its formulation was intended to produce a durable, workable paste that could be applied by hand or trowel, smoothed to a finish, and allowed to cure to a hard surface ready for painting or further treatment.
Artra-Synkoloid marketed this product during an era when asbestos-containing materials were widely accepted across the construction industry. The compound was commercially available from approximately 1962 through the early 1980s, a period during which regulatory scrutiny of asbestos in consumer and industrial products was gradually increasing. As scientific understanding of asbestos-related disease advanced and regulatory bodies including the Environmental Protection Agency (EPA) and the Occupational Safety and Health Administration (OSHA) began imposing stricter controls, asbestos-containing patching and finishing compounds like this one were phased out of production.
The product falls within the broader category of joint compounds and cementitious patching materials, a product class that has been extensively documented in asbestos litigation and regulatory proceedings as a source of occupational asbestos exposure.
Asbestos Content
Stucco & Cement Patch by Artra-Synkoloid contained chrysotile asbestos as a component of its formulation. Chrysotile, also referred to as white asbestos, is the most commercially widespread form of asbestos and belongs to the serpentine mineral group. During the decades when this product was manufactured, chrysotile was routinely incorporated into cementitious and patching compounds because of its ability to reinforce the material matrix, improve workability, resist cracking, and provide thermal stability.
Although chrysotile fibers have a curved, layered structure that differs from the straight, needle-like fibers of amphibole asbestos varieties, regulatory and scientific consensus has long established that chrysotile is a human carcinogen capable of causing mesothelioma, asbestosis, and lung cancer following sufficient inhalation exposure. OSHA’s current permissible exposure limit (PEL) for asbestos applies to all fiber types, including chrysotile, and the agency classifies asbestos as a known carcinogen with no safe level of occupational exposure established below its regulatory thresholds.
The presence of chrysotile asbestos in a patching and cementitious compound is particularly significant because such products are inherently disturbed during use—mixed, applied, sanded, and scraped—actions that can release respirable fibers into the breathing zone of anyone in proximity.
How Workers Were Exposed
Industrial workers who handled, applied, or worked in proximity to Stucco & Cement Patch during its production years faced potential inhalation exposure to chrysotile asbestos fibers. The nature of cementitious patching products creates multiple distinct points of fiber release throughout the product’s use lifecycle.
Mixing and preparation represented one of the most significant exposure pathways. When workers opened containers of dry or semi-dry patching compound and mixed the material—whether by hand, mechanical mixer, or direct addition of water—airborne dust containing asbestos fibers could be generated. In industrial settings, this mixing often occurred in enclosed or poorly ventilated areas, concentrating airborne fiber levels.
Application activities also created exposure risk. Troweling, spreading, and working the compound onto surfaces disturbed the material and could release fibers, particularly if the product was applied in layers or reworked before curing.
Sanding and abrading cured material is widely recognized as among the most hazardous activities associated with asbestos-containing patching products. Once Stucco & Cement Patch had dried and hardened, mechanical sanding, grinding, or scraping to smooth or level the surface could release substantial quantities of fine, respirable asbestos fibers. Industrial environments—factories, plants, and manufacturing facilities—often involved repair and maintenance work where such abrasive finishing was performed without adequate respiratory protection, particularly before OSHA’s asbestos standards were strengthened in the 1970s and 1980s.
Bystander exposure was also a documented concern. Workers performing adjacent tasks in the same industrial space as those applying or finishing asbestos-containing patching compounds could inhale fibers that remained suspended in the air for extended periods following disturbance.
The regulatory context is important. Prior to OSHA’s initial asbestos standard issued in 1971 and subsequent revisions that reduced permissible exposure limits, many industrial workers labored without respiratory protection, engineering controls such as local exhaust ventilation, or adequate warning about the health hazards of asbestos-containing materials. Employers and product manufacturers in this period had variable levels of awareness—and disclosure—regarding the known dangers of asbestos inhalation.
Documented Trust Fund / Legal Options
There is currently no dedicated asbestos bankruptcy trust fund associated with Artra-Synkoloid’s Stucco & Cement Patch. Individuals seeking compensation for asbestos-related illness connected to this product must pursue their claims through civil litigation rather than through a trust fund claims process.
Litigation records document that asbestos-containing joint compounds, patching materials, and cementitious products have been the subject of extensive civil asbestos litigation in courts across the United States. Plaintiffs alleged that manufacturers of such products, including those in the broader patching and finishing compound category, knew or should have known of the hazards of asbestos inhalation and failed to adequately warn workers or provide instructions for safe handling.
Plaintiffs alleged that this failure to warn constituted negligence and product liability, resulting in diagnoses of mesothelioma, asbestosis, lung cancer, and other asbestos-related diseases years or decades after initial exposure—consistent with the well-documented latency period for asbestos-related illness, which can range from ten to fifty years following first exposure.
Individuals who were exposed to Stucco & Cement Patch by Artra-Synkoloid and have subsequently received a diagnosis of an asbestos-related disease should consult with an attorney experienced in asbestos litigation. Key considerations in building a civil claim typically include:
- Documenting product identification: Work history records, co-worker testimony, union records, purchasing records, and employer documentation can help establish specific product exposure.
- Medical documentation: A confirmed diagnosis of an asbestos-related disease from a qualified physician is essential to any claim.
- Statute of limitations: Time limits for filing vary by state and typically begin running from the date of diagnosis or date the plaintiff knew or should have known of the connection between their illness and asbestos exposure. Consulting an attorney promptly after diagnosis is strongly advised.
- Additional defendants: Workers exposed to this product may also have been exposed to asbestos-containing materials from other manufacturers, and additional trust fund claims or litigation claims against other parties may be available depending on individual work history.
Litigation records document that industrial workers with asbestos-related disease diagnoses have pursued and in some cases resolved claims arising from exposure to joint compounds and patching products of this type. The absence of a trust fund means that resolution of claims, whether through settlement or verdict, proceeds through the civil court system.